Detalles de la búsqueda
1.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
N Engl J Med
; 388(7): 595-608, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791160
2.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Clin Infect Dis
; 2024 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38253338
3.
Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.
J Infect Dis
; 225(12): 2067-2076, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34146100
4.
Experts' opinion for improving global adolescent vaccination rates: a call to action.
Eur J Pediatr
; 179(4): 547-553, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072304
5.
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
J Infect Dis
; 220(11): 1816-1825, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31418022
6.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
J Infect Dis
; 219(11): 1799-1803, 2019 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30715452
7.
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
J Infect Dis
; 217(10): 1616-1625, 2018 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29401325
8.
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
J Infect Dis
; 217(11): 1750-1760, 2018 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29529222
9.
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
BMC Infect Dis
; 18(1): 186, 2018 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669531
10.
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
J Infect Dis
; 216(11): 1352-1361, 2017 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029224
11.
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
J Infect Dis
; 214(4): 525-36, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26908726
12.
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Int J Cancer
; 139(12): 2812-2826, 2016 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27541373
13.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Clin Immunol
; 169: 16-27, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236001
14.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Lancet Oncol
; 16(7): 775-86, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26071347
15.
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
J Infect Dis
; 210(4): 517-34, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24610876
16.
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
BMC Infect Dis
; 14: 551, 2014 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25927224
17.
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
J Infect Dis
; 208(9): 1391-6, 2013 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24092907
18.
[Cell-based influenza vaccines: an effective vaccine option for under 60-year-olds]. / Zellkulturbasierte Influenzaimpfstoffe: eine effektive Impfstoffoption für unter 60-Jährige.
Wien Klin Wochenschr
; 136(Suppl 2): 35-42, 2024 Feb.
Artículo
en Alemán
| MEDLINE | ID: mdl-38393348
19.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Influenza Other Respir Viruses
; 18(2): e13236, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38314063
20.
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
BMC Infect Dis
; 13: 435, 2013 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-24041010